The SafeBoosC phase II clinical trial: An analysis of the interventions related with the oximeter readings

Joan Riera, Simon Hyttel-Sorensen, María Carmen Bravo, Fernando Cabañas, Paloma López-Ortego, Laura Sanchez, Marta Ybarra, Eugene Dempsey, Gorm Greisen, Topun Austin, Olivier Claris, Monica Fumagalli, Christian Gluud, Petra Lemmers, Gerhard Pichler, Anne Mette Plomgaard, Frank Van Bel, Martin Wolf, Adelina Pellicer

Research output: Contribution to journalArticle

Abstract

Background: The SafeBoosC phase II randomised clinical trial recently demonstrated the benefits of a combination of cerebral regional tissue oxygen saturation (rStO2) by near-infrared spectroscopy (NIRS) and a treatment guideline to reduce the oxygen imbalance in extremely preterm infants. Aims: To analyse rStO2-alarm-related clinical decisions and their heterogeneity in the NIRS experimental group (NIRS monitoring visible) and their impact on rStO2 and SpO2. Methods: Continuous data from NIRS devices and the alarms (area under the curve of the rStO2 out of range had accumulated 0.2%h during 10 min), clinical data at discrete time points and interventions prompted by the alarms were recorded. Results: Sixty-seven infants had data that fulfilled the requirements for this analysis. 1107 alarm episodes were analysed. The alarm triggered a treatment guideline intervention in 25% of the cases; the type of intervention chosen varied among clinical sites. More than 55% of alarms were not followed by an intervention ('No action'); additionally, in 5% of alarms the rStO2 value apparently was considered non-reliable and the sensor was repositioned. The percentage of unresolved alarms at 30 min after 'No action' almost doubled the treatment guideline intervention (p2), were observed only after treatment guideline interventions. Conclusions: This study shows that 25% of rStO2 alarms were followed by a clinical intervention determined by the treatment guideline. However, the rStO2 and SpO2 returned to normal ranges after the intervention, supporting the notion that decisions taken by the clinicians were appropriate. Trial registration number: ClinicalTrial.gov NCT01590316.

Original languageEnglish
Pages (from-to)F333-F338
JournalArchives of Disease in Childhood: Fetal and Neonatal Edition
Volume101
Issue number4
DOIs
Publication statusPublished - Jul 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynaecology

Cite this

Riera, J., Hyttel-Sorensen, S., Bravo, M. C., Cabañas, F., López-Ortego, P., Sanchez, L., Ybarra, M., Dempsey, E., Greisen, G., Austin, T., Claris, O., Fumagalli, M., Gluud, C., Lemmers, P., Pichler, G., Plomgaard, A. M., Van Bel, F., Wolf, M., & Pellicer, A. (2016). The SafeBoosC phase II clinical trial: An analysis of the interventions related with the oximeter readings. Archives of Disease in Childhood: Fetal and Neonatal Edition, 101(4), F333-F338. https://doi.org/10.1136/archdischild-2015-308829